January 16, 2024 11:09 AM EST
News Briefing

Doud­na’s new ven­ture; Aclaris CEO to step down; Tome’s $114M liv­er dis­or­der deal with Genevant

ENDPOINTS

Plus, news about Ori­on, Stal­i­cla, Cyra­no Ther­a­peu­tics and In­stil Bio:

Jen­nifer Doud­na’s lat­est ven­ture: Her lab pub­lished a study Thurs­day in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times